Arbutus Biopharma appoints Daniel Burgess as director
Mr. Burgess has more than 25 years of executive level operating experience in biotech companies, including substantial experience in the anti-infective field.
Mr. Burgess is currently a Venture Partner at SV Life Sciences, is Chairman of the Board of Nabriva Therapeutics and is on the board of Cidara Therapeutics as well as several private biotechnology companies.
In addition, he is Chairman of Biocom, the life science industry organization of California that represents more than 800 member companies.
Prior to his current roles, Mr. Burgess was President of Rempex Pharmaceuticals, a company he co-founded in 2011 and subsequently sold to The Medicines Company in December 2013.
Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. (now Allergan) in 2011.
Previously, he was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc.
Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units.
Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School. ■
LATEST MOVES FROM British Columbia
- Napier Ventures director and CFO Michael Raftery resigns
- Group Ten Metals appoints Tim Thiessen as CFO
- Cardiome Pharma appoints Justin Renz as CFO
- Apivio Systems appoints two to board
- Nevsun Resources appoints Peter G. Kukielski as CEO
More inside POST